Abstract
This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Current Pharmaceutical Design
Title:Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors
Volume: 19 Issue: 26
Author(s): Haizhen A. Zhong, Jack Arbiser and J. Phillip Bowen
Affiliation:
Keywords: MMP-2, MMP-3, MMP-13, rheumatoid arthritis, osteoarthritis, cancer, docking, and zinc binding group.
Abstract: This review highlights some recent advances in the design and development of matrix metalloproteinase inhibitors, especially those targeting MMP-2, MMP-9, and MMP-13. Various zinc-binding groups and non-zinc-binding groups are discussed. Interactions between residues in the critical S1' specificity pocket and MMP inhibitors are given special attention. The influence of ionization states of hydroxamates and retrohydroxamates on the docking outcome and the presence of zinc ions in the active site are explored in light of enhancing enrichment factors for docking studies. Details are given to structural factors for the development of more selective and more potent MMP inhibitors.
Export Options
About this article
Cite this article as:
Zhong A. Haizhen, Arbiser Jack and Bowen Phillip J., Selectivity, Binding Affinity, and Ionization State of Matrix Metalloproteinase Inhibitors, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/1381612811319260004
DOI https://dx.doi.org/10.2174/1381612811319260004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Biocompatible Targeting Hydrogels for Breast Cancer Treatment
Mini-Reviews in Medicinal Chemistry Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Adipokines in Arthritis: New Kids on the Block
Current Rheumatology Reviews The Prediction of Human Intestinal Absorption Based on the Molecular Structure
Current Drug Metabolism Editorial (Thematic Issue: Focal Adhesion Kinase and Cross-Linked Signaling In Cancer)
Anti-Cancer Agents in Medicinal Chemistry Subject Index To Volume 7
Current Pharmaceutical Design Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology Impact of Epigenetic Dietary Components on Cancer through Histone Modifications
Current Medicinal Chemistry Flow Shear Induced Changes in Membrane Fluidity: Dependence on Cell- Substrate Adhesion Strength
Current Analytical Chemistry Recent Progress in Selenophenes Synthesis from Inorganic Se-Precursors
Current Organic Synthesis Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A
Anti-Cancer Agents in Medicinal Chemistry Targeting Angiogenesis in Ovarian Carcinoma
Current Cancer Therapy Reviews Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Characterization of Liver- and Cancer-type-Organic Anion Transporting Polypeptide (OATP) 1B3 Messenger RNA Expression in Normal and Cancerous Human Tissues
Drug Metabolism Letters Defensins: Key Molecules in Ocular Surface Protection
Current Immunology Reviews (Discontinued) A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation